CareDx is a precision medicine diagnostics company that provides non-invasive molecular diagnostic testing for long-term transplant patients. The key driver this quarter was testing services revenue of $100 million (+61% year-over-year) on approximately 58,000 tests performed (+17%). Growth was fueled by demand across the transplant program, a favorable insurance reimbursement environment, and expanded use across routine surveillance and indication testing. Patient and digital solutions revenue also grew 50% year-over-year to $19 million, supporting diversification of the business mix.

On the earnings side, adjusted metrics that strip out one-time effects are what matter. GAAP net income of $111 million and diluted EPS of $2.07 include approximately $113 million of gain from the June 30 divestiture of the lab products business and should be separated from core operations. By contrast, adjusted net income of $20 million, adjusted diluted EPS of $0.37, and adjusted EBITDA of $25 million (vs. $5 million a year ago) reflect underlying performance from testing revenue growth, gross margin improvement, and cost discipline. Operating cash flow of approximately $31 million also demonstrates cash-generation capability.

Taking the headline growth rate at face value can lead to overvaluation. The 61% increase in testing services revenue includes $16 million of revenue recognition for tests performed in prior periods; excluding this, the testing services revenue growth rate drops to roughly 28%. Growth is real, but investors need the discipline to separate one-time recognition items from recurring growth.

The lab products business has also been fully divested to Eurobio Scientific, so that segment's results will drop out starting next quarter. The company is repositioning itself as a precision molecular diagnostics player focused on transplant, specialty oncology, and cell therapy, and the Natera acquisition broadened its NaviDx foundation. However, integration costs, the pace of synergy realization, and the timing of cell therapy market entry remain to be validated. SG&A and R&D expenses are also scaling with revenue, meaning that if growth slows, the earnings expansion effect may not materialize as expected.

Management presented this quarter's results as evidence that the strategy is working, emphasizing that CareDx has been transformed into a differentiated precision molecular diagnostics company focused on transplant, specialty oncology, and cell therapy. The tone was confident and assertive, clearly flagging NaviDx integration and entry into cell therapy as the next growth pillars.

What the market zeroed in on was less the beat itself than the fact that full-year guidance was raised simultaneously and significantly on both the revenue and adjusted EBITDA lines. News on the regulatory and evidence side — confirmation of Medicare reimbursement for AlloSure and AlloMap, and expanding clinical evidence for transplant testing — reinforced the narrative that core demand can continue structurally. However, the guidance raise may include some business repositioning effects, so going forward it will be safer to track test volumes, organic revenue, and Natera's contribution separately.

The market appears to have interpreted the sizable revenue and adjusted earnings beat versus expectations, along with the simultaneous full-year guidance raise, as confirmation of the growth trajectory. Even stripping out the one-time divestiture gain, adjusted EBITDA and cash flow improved, and the story of transplant molecular testing demand combined with a favorable reimbursement environment has helped ease some of the stock's burden. That said, with the prior-period revenue recognition and lab products exclusion as numerical adjustment items, attention is likely to shift after the initial reaction to confirmation of next quarter's organic growth.